Supernus is a specialty pharmaceuticals company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company's lead products, Oxtellar XR® and Trokendi XR®, are for the treatment of epilepsy. Supernus is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in patients with attention deficit hyperactivity disorder (ADHD) and SPN-812 for the treatment of ADHD.
Supernus has two products for the treatment of epilepsy: Oxtellar XR®, launched in the first quarter of 2013, and Trokendi XR®, launched in the third quarter of 2013.
Oxtellar XR® is a novel, oral, once-daily, extended-release formulation of oxcarbazepine. Oxcarbazepine was developed by Novartis Pharmaceuticals Corporation and launched under the brand name Trileptal®.
Oxcarbazepine is an active voltage-dependent sodium channel blocker that, despite its effectiveness in treating epilepsy, is associated with many side effects that tend to limit its use, such as dizziness, double vision, somnolence, nausea, and vomiting.
Trokendi XR® is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Trokendi XR® delivers topiramate, one of the most effective anti-epilepsy drugs, which was developed by Johnson & Johnson and marketed under the brand name Topamax®.
Topiramate as an anti-epileptic drug is indicated for monotherapy and adjunctive therapy of epilepsy, as well as for the treatment of migraine.
Side effects associated with topiramate, which have tended to limit its use, include dizziness, fatigue, somnolence, and slowing of certain cognitive functions.
Oxtellar XR® and Trokendi XR® are designed to improve patient compliance compared to the current immediate-release products that are taken multiple times per day.
Oxtellar XR® and Trokendi XR® deliver lower peak plasma concentrations and lower input rate over an extended time period, resulting in smoother and more consistent blood levels of oxcarbazepine or topiramate during the day compared to immediate-release products. Moreover, Oxtellar XR® and Trokendi XR® avoid blood level fluctuations that can be associated with many of the side effects or breakthrough seizures that patients can suffer from when taking immediate-release products.
Please visit the Product Pipeline section of our website.
- Drive continued growth of our commercialized products to maximize their long term sales potential.
- Continue to advance our product candidates in our psychiatry portfolio, including SPN-810 and SPN-812. We intend to continue to develop our product candidates in our psychiatry portfolio to enable further diversification of our pipeline and future growth.
- Establish strategic partnerships to accelerate and maximize the potential of our product candidates worldwide.
- Evaluate and develop through our internal research and development activities differentiated CNS product candidates that we believe have significant commercial potential. Leverage our management team's expertise to develop and commercialize our broad portfolio of product candidates.
Supernus was founded in 2005 and started operations following the acquisition of substantially all of the assets of Shire Laboratories Inc. The company previously had been a U.S. subsidiary of Shire plc. Supernus and its management team have more than 25 years of experience in developing and commercializing CNS products.
Supernus is traded on the Nasdaq Global Select Market under the symbol "SUPN."
Please visit the Investor Relations section of the website for investor relations materials, including current press releases, quarterly and annual reports, and SEC filings.
Please visit the Events and Presentations section of this website for the date of the next financial results release.
Supernus has never declared a cash dividend on its common stock and has no plans to initiate a dividend program.
Supernus does not have a direct stock purchase program.
Please contact the company's transfer agent:
Shareholder correspondence should be mailed to:
P.O. BOX 30170
College Station, TX 77842-3170
Overnight correspondence should be sent to:
211 Quality Circle, Suite 210
College Station, TX 77845
KPMG LLP is the company's independent accounting firm.
Saul Ewing is the company's outside legal counsel.
Supernus CUSIP number is 868459 10 8.
Please contact Greg Patrick at 301.838.2522 or email@example.com.
You can view Supernus’ Board of Directors by visiting the Corporate Governance section of our Investor Relations website.
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financials & Filings section of our Investor Relations website or directly from the SEC at www.sec.gov.
Please submit your question using the form located here.